Follow-up therapy according to BOR and first and second line therapy with T-VEC | |||||||
Patients with follow-up therapy | BRAF MEK inhibitor | PD-1 Inhibitor | PD-1+CTLA4 Inhibitor | CTLA4 Inhibitor | Chemo- therapy | Electro-chemotherapy | |
First line therapy | 14/45 (15.9%) | 1 (1.1%) | 10 (11.4%) | 1 (1.1%) | 2 (2.3%) | ||
with T-VEC | |||||||
Second line therapy | 19/43 (21.6%) | 7 (8.0%) | 6 (6.8%) | 3 (3.4%) | 2 (2.3%) | 1 (1.1%) | |
with T-VEC | |||||||
In total | 33/88 (37.5%) | 8 (9.1%) | 16 (18.2%) | 4 (4.5%) | 2 (2.3%) | 1 (1.1%) | 2 (2.3%) |
BOR | |||||||
CR | 6/38 (6.8%) | 1 (1.1%) | 4 (4.5%) | 1 (1.1%) | |||
SD | 3/8 (3.4%) | 1 (1.1%) | 1 (1.1%) | 1 (1.1.%) | |||
PR | 6/18 (6.8%) | 3 (3.4%) | 2 (2.3%) | 1 (1.1%) | |||
PD | 18/24 (20.4%) | 3 (3.4%) | 9 (10.2%) | 2 (2.3%) | 2 (2.3%) | 1 (1.1%) | 1 (1.1%) |
In total | 33/88 (37.5%) | 8 (9.1%) | 16 (18.2%) | 4 (4.5%) | 2 (2.3%) | 1 (1.1%) | 2 (2.3%) |